Anti-VEGF’s have changed the prognosis of exudative age-related macular degeneration (AMD). Ranibizumab and aflibercept have proven their functional efficacy, but their use has revealed in real life a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results